Ante-natal screening and post-natal follow-up of hepatitis B in the West Midlands of England

QJM: An International Journal of Medicine

Volumn 101, Issue 4, 2008, Pages 307-312

  Bhattacharya, S ^a   O'Donnell, K ^a   Dudley, T ^a   Kennefick, A ^a   Osman, H ^a   Boxall, E ^a   Mutimer, David ^a,b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DELTA AGENT HEPATITIS; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS DELTA VIRUS; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; NONHUMAN; OBSERVATIONAL STUDY; PRENATAL PERIOD; PRIORITY JOURNAL; PUERPERIUM; RETROSPECTIVE STUDY; UNITED KINGDOM; VIRUS REPLICATION;

EID: 41149134973     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcn007     Document Type: Article

References (19)

1. Health Protection Agency. Migrant Health. Infectious Diseases in non-UK Born Populations in England, Wales and Northern Ireland. A Baseline Report - 2006. London, Health Protection Agency, 2006.
2. Birmingham City Council. Census 2001: About Birmingham. http://www.birmingham.gov.uk/GenerateContent? CONTENT_ITEM_ID=26205&CONTENT_ITEM_TYPE=0&MENU_ID=12672 (24 April 2007, date last accessed).
3. National Institute for Clinical Excellence. Antenatal Care: Routine Care for the Healthy Pregnant Woman. National Collaborating Centre for Women's and Children's Health. NICE. London, Clinical guideline, October 2003.
4. Boxall E, Hodgkiss S, Tonks A. Antenatal screening in the West Midlands. Fourth Report. Birmingham, Perinatal Institute, May 2007. http://www.perinatal.nhs.uk/screening/ resources/Infectious_disease_report.pdf
5. Hahné S, Ramsay M, Balogun K, Edmunds WJ, Mortimer P. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: Implications for immunisation policy. J Clin Virol 2004; 29:211-20.
6. Health Protection Agency. Epidemiological data- Hepatitis B. http://www.hpa.org.uk/infections/topics_az/hepatitis_b/menu.htm. (Accessed on 16 March 2007).
7. Song YM, Sung J, Yang S, Choe YH, Chang YS, Park WS. Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus. Eur J Pediatr 2007; 166:813-8.
8. Department of Health. Immunisation Against Infectious Diseases- "The Green Book". Hepatitis B, Ch.18. London, Department of Health, 2006.
9. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al. Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United. States: Recommendations of the Advisory Committee on Immunization Pratices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54(RR-16):1-31.
10. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev 2006; CD004790.
11. Yang YJ, Liu CC, Chen TJ, et al. Role of hepatitis B immunoglobulin in infants born to hepatitis B e antigen-negative carrier mothers in Taiwan. Pediatr Infect Dis J 2003; 22:584-8.
12. Boxall EH, A Sira J, El-Shuhkri N, Kelly DA. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis 2004; 190:1264-9.
13. Beath SV, Boxall EH, Watson RM, Tarlow MJ, Kelly DA. Fulminant hepatitis B in infants born to anti-HBe hepatitis B carrier mothers. Br Med J 1992; 304:1169-70.
14. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990; 87:6599-603.
15. Lok ASF, McMahon BJ. Chronic hepatitis B: Update of recommendations. AASLD practice guideline. Hepatology 2004; 39:1-5.
16. Thomas HC. Best practice in the treatment of chronic hepatitis B: A summary of the European Viral Hepatitis Educational Initiative (EVHEI). J Hepatol 2007; 47:588-97.
17. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: Prospective cohort study. BMJ 2004; 328:983-88.
18. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130 678-86.
19. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.